SPRY ARS Pharmaceuticals, Inc.
Healthcare$8.17+2.90%ClosedMarket Cap: $811.3M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
12.86
P/S
7.97
EV/EBITDA
-4.43
DCF Value
$-4.66
FCF Yield
-22.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.1%
Operating Margin
-204.5%
Net Margin
-200.0%
ROE
-153.6%
ROA
-68.8%
ROIC
-84.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $22.7M | 72.3% | $-60.1M | $-60.6M | $— | — |
| Q4 null | $28.1M | 88.6% | $-41.5M | $-41.3M | $— | — |
| FY null | $84.3M | 75.8% | $-179.4M | $-171.3M | $— | — |
| Q3 null | $32.5M | 74.8% | $-53.2M | $-51.2M | $— | — |
| Q2 null | $15.7M | 68.3% | $-47.6M | $-44.9M | $— | — |
| Q1 null | $8.0M | 49.3% | $-37.2M | $-33.9M | $— | — |
| Q4 null | $86.6M | 95.5% | $47.2M | $49.9M | $— | — |
| FY null | $89.1M | 76.9% | $-3.1M | $8.0M | $— | — |
| Q3 null | $2.1M | 94.6% | $-21.7M | $-19.1M | $— | — |
| Q2 null | $500.0K | 100.0% | $-15.3M | $-12.5M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-13.2M | $-10.3M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-10.2M | $-7.2M | $-0.07 | — |